Subscribe to RSS
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.4103/0970-0358.101279
Evaluation of recombinant human platelet-derived growth factor as an agent for wound bed preparation in traumatic wounds
Publication History
Publication Date:
27 November 2019 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00042863/201202/lookinside/thumbnails/10-4103-0970-0358-101279-00203-1.jpg)
ABSTRACT
Background: In patients with life-threatening injuries, simple wounds requiring split-thickness skin grafts (SSG) often get neglected. These then need SSG once they are covered with granulation tissue through wound bed preparation. Traditionally, this is done by daily moist dressings. Recombinant human platelet-derived growth factor (rhPDGF) has been shown to improve healing in chronic wounds. Aim: The present study was undertaken to compare the efficacy of rhPDGF in wound bed preparation with the current practice of daily saline dressings. Setting and Design: A prospective randomised, single-blinded study was carried out for evaluation in traumatic wounds. Materials and Methods: The patients were randomised and divided into a control group that was subjected to saline dressings and a test group that was treated with rhPDGF gel. Both the groups were then compared. The statistical analysis was carried out using SPSS 16.0 and the quantitative variables were analysed using unpaired "t" test, while the pre- and post-intervention effects were assessed using paired "t" test. The 95% CI values were also included. Results: Of the 155 wounds studied, time taken for appearance of granulation tissue (in days) in the test group had a mean of 13.81 ± 2.68, while that in the control group was 13.36 ± 3.81 (P = 0.401). Complete re-epithelialisation without discharge occurred in the control group with a mean value of 28.9 ± 3.67 days, while that in the test group had a mean of 31.17 ± 4.82 days. Conclusion: There was no difference in wound healing between the patients treated with rhPDGF compared to those treated by conventional moist dressings.
- 1 Hansen SL, Mathes SJ. Problem wounds and principles of closure. In: Plastic surgery. New York: Elsevier; 2006. p. 901-50.
- 2 Nagai MK, Embil JM. Becaplermin: Recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers. Expert Opin Biol Ther 2002;2:211-8.
- 3 Wiemen TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet derived growth factor BB (Becaplermin) in patients with chronic neuropathic diabetic ulcers. Diabetes Care 1998;21:822-7.
- 4 Harding KG. The future of wound healing. In: Leaper DJ, Harding KJ, editors. Wounds: biology and management. Oxford: Oxford University Press; 1998. p. 191-9.
- 5 Currie CJ, Morgan CL, Peters JR. The epidemiology and cost of inpatient care for peripheral vascular disease, infection, neuropathy and ulceration in diabetes. Diabetes Care 1998;21:42-8.
- 6 Reiber GE. Diabetic foot care: Financial implications and practical guidelines. Diabetes Care 1992;15:29-31.
- 7 Godina M. Early microsurgical reconstruction of complex trauma of the extremities. Plast Reconstr Surg 1986;78:285-92.
- 8 Embil JM, Papp K, Sibbald G, Tousignant J, Smiell JM, Wong B, et al. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: An open-label clinical evaluation of efficacy. Wound Repair Regen 2000;8:162-8.
- 9 Rees RS, Robson MC, Smiell JM, Perry BH. Becaplermin gel in the treatment of pressure ulcers: A phase II randomized, double-blind, placebo-controlled study. Wound Repair Regen 1999;7:141-7.
- 10 Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: A combined analysis of four randomized studies. Wound Repair Regen 1999;7:335- 46.
- 11 Peus D, Jungtäubl H, Knaub S, Leuker A, Gerecht K, Ostendorf R, et al. Localization of platelet-derived growth factor receptor subunit expression in chronic venous leg ulcers. Wound Repair Regen 1995;3:265-72.
- 12 Steed DL. Clinical evaluation of recombinant human platelet derived growth factor for the treatment of lower extremity ulcers. Plast Reconstr Surg 2006;117:143S-9S.
- 13 Schaffer M, Coerper S, Becker HD. Gene therapy in diabetic foot. Kongressbd Dtsch Ges Chir Kongr 2001;118:825-8.
- 14 Lavery LA, Barnes SA, Keith MS, Seaman JW, Armstrong DG. Prediction of healing for postoperative diabetic foot wounds based on early wound area progression. Diabetes Care 2008;31:26-9.
- 15 Attinger CE, Janis JE, Steinberg J, Schwartz J, Al-Attar A, Couch K. Clinical approach to wounds: Debridement and wound bed preparation including the use of dressings and wound-healing adjuvants. Plast Reconstr Surg 2006;117:72S-109S.